it is concluded that ( 1 ) some patients who do not respond to the antianginal action of low-dose isdn may respond to a high dose and tolerate it , ( 2 ) this responsiveness and tolerability may last for over a year , and ( 3 ) isdn may be clinically useful in patients with coronary disease even when exercise performance is not significantly improved .
C0022252
isdn
C0010068
coronary disease